ProvideGx® Partners with Pfizer Inc. to Secure the Supply of Five Essential Medications

ProvideGX®与辉瑞公司合作,确保五种基本药物的供应

2021-01-22 03:01:29 BioSpace

本文共1982个字,阅读需5分钟

The five medicines include: diazepam, labetalol, lorazepam, fentanyl citrate and 0.9 percent sodium chloride injection. Labetalol is a beta blocker that is used to treat high blood pressure. Lorazepam and diazepam are controlled substances used as anti-anxiety medications. Fentanyl is a controlled substance used to prevent pain for short periods of time, usually before anesthesia is administered or immediately after surgical procedures. The 0.9 percent sodium chloride injection is used to dilute other medications before injection. These five medications are critical for patient care and in some cases are necessary as part of COVID-19 treatments. As COVID-19 cases increase, demand for some of these medications has risen. For instance, fentanyl is often used to provide pain relief to patients receiving mechanical ventilation in their treatment for COVID-19, causing demand for this drug to spike 7.5X during peak periods. “This past year has unquestionably placed unprecedented demand on the drug supply chain, particularly for drugs used during mechanical ventilation of COVID-19 patients,” said Premier’s President, Michael J. Alkire. “Our partnership with Pfizer will help ensure a sustainable supply of five drugs that are essential not just during the pandemic, but also for routine and elective care longer term.” Guided by health systems with more than 1,600 hospitals across the nation, Premier’s ProvideGx program creates long-term committed buying contracts that provide participating manufacturers with the surety needed to increase production or move into new markets. Premier’s programs, including ProvideGx, currently provide members access to more than 150 drugs that are or have been recently designated as shortage drugs, with a pipeline of more than 50 additional drugs. The program has also ensured an adequate safety stock of medicines and has successfully protected supply even as demand surged more than 150 percent during the COVID-19 pandemic. Pfizer has made significant investments in its injectables manufacturing network to support increased capacity and order fulfillment rates. The enhanced agreement with Premier helps facilitate increased access to these medicines for Premier member institutions and their patients. “Our focus at Pfizer on delivering a consistent supply of injectable medicines took on even greater importance as patient need increased throughout the pandemic,” said Angela Lukin, Global President, Pfizer Hospital. “The addition of these injectable medicines to our Premier agreement helps secure supply for products critical to patient care during the pandemic, while driving long-term market sustainability.” The financial terms of Premier’s agreement with Pfizer are not being disclosed. Forward-Looking Statements Matters discussed in this release that are not statements of historical or current facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Premier to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Premier’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Premier’s control. More information on potential factors that could affect Premier’s financial results is included from time to time in the “Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Premier’s periodic and current filings with the SEC and available on Premier’s website at investors.premierinc.com. Forward-looking statements speak only as of the date they are made. Premier undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. About Premier Inc. Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,100 U.S. hospitals and health systems and approximately 200,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company. View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005759/en/ Amanda Forster, Public_Relations@PremierInc.com Source: Premier Inc. View this news release online at: http://www.businesswire.com/news/home/20210121005759/en
5种药品包括:地西泮,拉贝洛尔,劳拉西泮,枸橼酸芬太尼,0.9%氯化钠注射液。拉贝洛尔是一种beta阻滞剂,用于治疗高血压。劳拉西泮和地西泮是用作抗焦虑药物的受管制物质。芬太尼是一种受管制的物质,用于预防短期疼痛,通常在麻醉前或手术后立即使用。0.9%氯化钠注射液用于其他药物注射前的稀释。 这五种药物对病人的护理至关重要,在某些情况下,作为COVID-19治疗的一部分是必要的。随着COVID-19病例的增加,对其中一些药物的需求也在上升。例如,芬太尼常用于为接受机械通气治疗的COVID-19的患者提供疼痛缓解,导致在高峰期对该药物的需求激增7.5x。 Premiers总裁Michael J.Alkire说,过去的一年无疑给药品供应链带来了前所未有的需求,特别是用于COVID-19病人机械通气的药品。我们与辉瑞的合作将有助于确保五种药物的可持续供应,这五种药物不仅在大流行期间是必不可少的,而且在长期的常规和选择性治疗中也是必不可少的。 Premiers ProvideGx计划在全国1600多家医院的卫生系统的指导下,制定了长期承诺购买合同,为参与的制造商提供增加产量或进入新市场所需的保证。包括ProvideGx在内的Premiers计划目前向会员提供150多种目前或最近被指定为短缺药品的药品,另外还有50多种补充药品。该计划还确保了充足的安全药品储备,并成功地保护了供应,即使在COVID-19大流行期间需求激增超过150%。 辉瑞在其注射剂制造网络上进行了重大投资,以支持提高产能和订单完成率。加强与PREMIY的协议有助于增加PREMIY成员机构及其患者获得这些药物的机会。 辉瑞医院全球总裁Angela Lukin说:“随着整个大流行期间患者需求的增加,辉瑞公司专注于持续供应注射用药物的工作变得更加重要。”在我们的Premier协议中增加这些注射药物有助于确保在大流行期间对病人护理至关重要的产品的供应,同时推动长期市场的可持续性。 Premier与辉瑞的协议的财务条款没有透露。 前瞻性陈述 本新闻稿中讨论的不是历史或当前事实陈述的事项是前瞻性陈述,符合1995年《私人证券诉讼改革法案》的含义。前瞻性陈述可能涉及已知和未知的风险,不确定性和其他因素,这些因素可能导致卓越理财的实际结果,业绩或成就与历史结果或与此类前瞻性陈述所明示或暗示的任何未来结果或预测存在重大差异。因此,读者不应过分依赖任何前瞻性陈述。除了明确描述此类风险和不确定性的陈述外,还敦促读者考虑使用条件时态或将来时态的陈述,或者包括诸如相信,相信,预期,估计,打算,预期或计划等术语的陈述,这些陈述具有不确定性和前瞻性。前瞻性陈述可能包括关于Premier对影响其业务的未来事件和趋势的信念和期望的评论,并且必然受到不确定性的影响,其中许多不确定性是Premier无法控制的。有关可能影响Premiers财务业绩的潜在因素的更多信息,不时包含在Premiers定期和当前提交给SEC的文件中的前瞻性陈述,风险因素和管理层对财务状况和运营结果的讨论和分析部分中,并可在Premiers网站investors.premierinc.com上查阅。前瞻性陈述仅在其发表之日起发言。卓越理财不承担公开更新或修订任何前瞻性陈述的义务,无论是由于新信息,未来事件或该日期之后发生的其他原因。 关于Premier Inc。 Premier Inc.(纳斯达克市场代码:PINC)是一家领先的医疗保健改善公司,它联合了4100多家美国医院和医疗系统以及大约200,000家其他提供商和组织的联盟来改造医疗保健。Premier通过集成的数据和分析,协作,供应链解决方案,咨询和其他服务,以更低的成本实现更好的护理和结果。Premier在快速发展的医疗保健行业中扮演着重要角色,它与各成员合作,共同开发长期创新,重新发明和改进向全国患者提供护理的方式。总部设在北卡罗来纳州夏洛特的Premier对改变美国的医疗保健充满热情。请访问Premiers新闻和投资者网站:www.premierinc.com;以及Twitter,Facebook,LinkedIn,YouTube,Instagram和Premiers博客,以获取更多关于该公司的信息。 在businesswire.com上查看源代码版本:https://www.businesswire.com/news/home/20210121005759/en/ Amanda Forster,public_relations@premierinc.com 资料来源:Premier Inc。 在线查看此新闻稿: http://www.businesswire.com/news/home/20210121005759/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文